Opinion|Videos|September 6, 2024
Key Factors to Consider when Switching to Biosimilars
Author(s)Sophia Humphreys, PharmD, MHA
Dr Humphreys discusses key factors to consider when switching to biosimilars.
Advertisement
Video content above is prompted by the following:
- To what extent should the pharmacy team prioritize supporting the switch from a reference product to a biosimilar, and what factors should be considered in making this decision?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
IMS 2025: Quadruplet Regimens Enhance Depth of Response in Multiple Myeloma
2
IMS 2025: Future Directions for CAR T Therapy in Relapsed and Refractory Multiple Myeloma
3
Updated IMWG Guidelines Spotlight MRD, Functional Imaging, and Light Chain Assays in Multiple Myeloma
4
FDA Approves Bosaya and Aukelso, Biosimilars to Reference Denosumab
5